XOMA Royalty Corporation Completes Tender Offer and Acquisition of Generation Bio

XOMA Royalty Acquires LAVA Therapeutics N.V.

November 21, 2025

Biotechnology

XOMA Royalty Corporation completed the acquisition of all outstanding common shares of LAVA Therapeutics N.V., paying $1.04 per share plus a contingent value right (CVR) that conveys rights to future milestone and royalty proceeds. The deal brings two partnered bispecific antibody programs (with Johnson & Johnson and Pfizer) and additional unpartnered programs into XOMA Royalty's milestone and royalty portfolio as part of its strategy to expand its biotechnology royalty assets.

Genmab A/S Acquires Merus N.V. via Tender Offer

December 12, 2025

Biotechnology

Genmab A/S, through its wholly owned purchaser Genmab Holding II B.V., completed a tender offer to acquire outstanding common shares of Merus N.V. for $97.00 per share and commenced a subsequent offering period. The acquisition adds Merus' lead late‑stage oncology asset petosemtamab to Genmab's portfolio, expanding its antibody therapeutics pipeline and expected to be accretive to EBITDA by 2029.

Quanterix Completes Acquisition of Akoya Biosciences

July 8, 2025

Healthcare Services

Quanterix completed its previously announced acquisition of Akoya Biosciences under the amended merger agreement, issuing about 7.8 million shares and paying about $20 million in cash in the aggregate to Akoya holders. The companies positioned the deal as creating an integrated platform for measuring biomarkers across the blood and tissue continuum and expanding addressable markets.

Harmony Biosciences Acquires Zynerba Pharmaceuticals

August 14, 2023

Pharmaceuticals

Harmony Biosciences Holdings, Inc. has signed a definitive agreement to acquire Zynerba Pharmaceuticals, Inc. in a cash tender offer valued at $60 million at closing ($1.1059 per share) plus a non-tradeable contingent value right (CVR) with potential additional payments of up to $140 million, for total potential consideration of up to $200 million. The deal is expected to close in the fourth quarter of 2023, subject to customary closing conditions and tendering by at least a majority of Zynerba’s outstanding shares.

BerGenBio and Oncoinvent Announce Proposed Merger and Fully Underwritten Rights Issue

June 30, 2025

Biotechnology

BerGenBio ASA and Oncoinvent ASA have entered into a merger agreement to combine the two companies via a statutory merger, with BerGenBio as the acquiring entity. The transaction is supported by major shareholders and is expected to be completed around mid-September 2025, alongside a fully underwritten NOK 130 million rights issue to fund Oncoinvent’s clinical development through 2027.

Roche Acquires Poseida Therapeutics

November 28, 2024

Biotechnology

Roche Holdings, Inc. has agreed to acquire San Diego-based Poseida Therapeutics for $9.00 per share in cash plus a contingent value right (CVR) for up to $4.00 per share, representing an aggregate equity value of up to $1.5 billion. The acquisition will bring Poseida's non-viral gene-editing platforms, allogeneic TSCM-rich CAR-T programs and in-house GMP cell therapy manufacturing into Roche's Pharmaceuticals Division to establish a new core capability in allogeneic cell therapy.